Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $21 from $17 and keeps an Overweight rating on the shares. The firm notes BrightSpring reported strong Q3 results and raised guidance for Pharmacy and Provider, with 2024 adjusted EBITDA raised 1.3%. Wells is also raising its 2025 adjusted EBITDA 0.8%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $20 from $13 at Deutsche Bank
- BrightSpring Health price target raised to $20 from $17 at Mizuho
- BrightSpring Health Services Reports Strong Q3 Growth
- BrightSpring Health reports Q3 adjusted EPS 11c, consensus 17c
- BrightSpring Health raises 2024 revenue view to $11B-$11.3B from $10.45B-$10.90B